Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05026125
Other study ID # RC31/20/0443
Secondary ID 2021-000727-12
Status Completed
Phase Phase 4
First received
Last updated
Start date January 13, 2022
Est. completion date August 11, 2023

Study information

Verified date October 2023
Source University Hospital, Toulouse
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will assess the condition of orotracheal intubation in obese patients undergoing an elective bariatric surgery without the use of neuromuscular blocking agents. During the induction of general anesthesia, Propofol - Remifentanil combination will be used. The patients will be randomized in 2 groups with different doses of Remifentanil.


Description:

The prevalence of obesity increases steadily. For anesthesiologists, the airway management of obese patients is known to be difficult and at risk. Tracheal intubation needs to be successful quickly. Neuromuscular blocking agents allow this option but with a risk of anaphylaxis and respiratory complications. In fact, for many surgical procedures those drugs are not necessary. Numerous studies in non-obese patients with the combination of Remifentanil and Propofol have shown adequate conditions for tracheal intubation without neuromuscular blocking drugs. This combination has never been studied in obese patient. After randomization, induction of general anesthesia will be performed with 2,5 mg/kg of Propofol in association with either 3 µg/kg of Ideal Body Weight of Remifentanil, or 3 µg/kg + 30% of Ideal Body Weight of Remifentanil. Minutes after the induction, orotracheal intubation will be performed, and the Intubation Difficulty Scale recorded. Other data on hemodynamic, respiratory and airway management will be are collected during the surgery. In the Post Anaesthetic Care Unit (PACU),Any symptoms of traumatic airway management or aspiration are collected. Those data will be again looked for and collected on the day of the patient's discharge.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date August 11, 2023
Est. primary completion date August 11, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Patient over 18 and under 60 years old. - ASA score = 3 - Elective bariatric surgery for patient with BMI between 35 and 60 or elective revision of a bariatric surgery for patient with a BMI over 30. - Patient with a written consent obtained with accurate information. Exclusion Criteria: - Patient with risk of aspiration - Difficult airway known (Cormack score 3 ou 4). - Opioids addiction. - Alcoholism - Chronic use of Opioids - Confirmed Allergy to Propofol or Remifentanil - Severe chronic hepatic, kidney or respiratory failure - Patient already enrolled in another clinical study interfering with this study.

Study Design


Intervention

Drug:
Remifentanil Injection
Injection of 3 µg/kg (Ideal Body Weight) of Remifentanil in the induction phase of anesthesia for orotracheal intubation for bariatric surgery
Remifentanil Injection plus 30%
Injection of 3 µg/kg (Ideal Body Weight) plus 30% of Remifentanil in the induction phase of anesthesia for orotracheal intubation for bariatric surgery

Locations

Country Name City State
France Hospital University of Toulouse Toulouse

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Toulouse

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary percentage of good to excellent conditions of intubation percentage of good to excellent conditions of intubation in obese patients using the Intubation Difficulty Scale (IDS). The IDS is graded in the operating theater during the induction of general anesthesia. Day 0
Secondary Hemodynamic events day 0 Incidence rate of haemodynamic events at day 0 Day 0
Secondary Hemodynamic events day 3 Incidence rate of haemodynamic events at day 3 Day 3
Secondary Respiratory events day 0 Incidence rate of respiratory events at day 0 day 0
Secondary Respiratory events day 3 Incidence rate of respiratory events at day 3 day 3
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2